Literature DB >> 7810824

Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti.

M M Khin1, N Jirakanjanakit, S Yoksan, N Bhamarapravati.   

Abstract

The capacity for oral infection, dissemination, and transmission of the dengue-2 candidate vaccine virus DEN-2 PDK53 and an isolate from a vaccinate individual, DEN-2 Ia8, were compared with the parent strain DEN-2 16681. Capacity for oral infection and dissemination to the brain and salivary gland tissues were significantly lower in the first two than in the parent strain (P < 0.001). Replication was more than 100 times higher for the parent strain when compared with the dengue-2 candidate vaccine virus. Transmission was not demonstrated in the mosquitoes orally infected with DEN-2 PDK53 and DEN-2 Ia8, whereas transmission was achieved in 57% (8 of 14) of mosquitoes infected with the parent virus strain. Using immunofluorescence, viral antigen was detected in the mosquitoes infected with DEN-2 PDK53 and DEN-2 Ia8. It was seen mainly in the form of specks scattered in some parts of the tissues, and was strikingly different from that seen in the parent strain, in which major parts of the tissues contained viral antigen in the form of rings and specks. The biological markers of DEN-2 PDK53 and DEN-2 Ia8 retained the biological characteristic of the vaccine after a mosquito passage and a human and mosquito passage, respectively.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7810824     DOI: 10.4269/ajtmh.1994.51.864

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  9 in total

1.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

Authors:  C Y Huang; S Butrapet; D J Pierro; G J Chang; A R Hunt; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.

Authors:  Claire Y-H Huang; Shawn J Silengo; Melissa C Whiteman; Richard M Kinney
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus.

Authors:  Elizabeth A Dietrich; Yee Tsuey Ong; Janae L Stovall; Hansi Dean; Claire Y-H Huang
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

6.  Metabolic Processes Are Differentially Regulated During Wild-Type and Attenuated Dengue Virus Infection in Aedes aegypti.

Authors:  Tanamas Siriphanitchakorn; Cassandra M Modahl; R Manjunatha Kini; Eng Eong Ooi; Milly M Choy
Journal:  Am J Trop Med Hyg       Date:  2022-01-10       Impact factor: 3.707

7.  Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegypti.

Authors:  Philip M Armstrong; Rebeca Rico-Hesse
Journal:  Am J Trop Med Hyg       Date:  2003-05       Impact factor: 2.345

8.  American genotype structures decrease dengue virus output from human monocytes and dendritic cells.

Authors:  Raymond Cologna; Rebeca Rico-Hesse
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).

Authors:  Claire Y-H Huang; Richard M Kinney; Jill A Livengood; Bethany Bolling; John J Arguello; Betty E Luy; Shawn J Silengo; Karen L Boroughs; Janae L Stovall; Akundi P Kalanidhi; Aaron C Brault; Jorge E Osorio; Dan T Stinchcomb
Journal:  PLoS Negl Trop Dis       Date:  2013-05-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.